(NASDAQ: AXSM) Axsome Therapeutics's forecast annual revenue growth rate of 48.07% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 57.08%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.39%.
Axsome Therapeutics's revenue in 2025 is $432,157,000.On average, 10 Wall Street analysts forecast AXSM's revenue for 2025 to be $30,221,133,128, with the lowest AXSM revenue forecast at $28,266,597,147, and the highest AXSM revenue forecast at $32,451,097,335. On average, 10 Wall Street analysts forecast AXSM's revenue for 2026 to be $47,114,326,905, with the lowest AXSM revenue forecast at $40,521,528,395, and the highest AXSM revenue forecast at $53,277,242,712.
In 2027, AXSM is forecast to generate $70,338,627,912 in revenue, with the lowest revenue forecast at $57,577,005,231 and the highest revenue forecast at $86,959,790,772.